Sinopharm Group Co. Ltd (X2S) - Net Assets
Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has net assets worth €129.26 Billion EUR (≈ $151.12 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€420.33 Billion ≈ $491.41 Billion USD) and total liabilities (€291.07 Billion ≈ $340.29 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sinopharm Group Co. Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €129.26 Billion |
| % of Total Assets | 30.75% |
| Annual Growth Rate | 14.48% |
| 5-Year Change | 40.85% |
| 10-Year Change | 209.91% |
| Growth Volatility | 7.9 |
Sinopharm Group Co. Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Sinopharm Group Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Sinopharm Group Co. Ltd total assets for the complete picture of this company's asset base.
Annual Net Assets for Sinopharm Group Co. Ltd (2013–2024)
The table below shows the annual net assets of Sinopharm Group Co. Ltd from 2013 to 2024. For live valuation and market cap data, see X2S company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €126.69 Billion ≈ $148.11 Billion |
+5.29% |
| 2023-12-31 | €120.32 Billion ≈ $140.67 Billion |
+9.31% |
| 2022-12-31 | €110.07 Billion ≈ $128.68 Billion |
+10.45% |
| 2021-12-31 | €99.65 Billion ≈ $116.51 Billion |
+10.79% |
| 2020-12-31 | €89.95 Billion ≈ $105.16 Billion |
+16.91% |
| 2019-12-31 | €76.94 Billion ≈ $89.95 Billion |
+12.69% |
| 2018-12-31 | €68.28 Billion ≈ $79.82 Billion |
+33.17% |
| 2017-12-31 | €51.27 Billion ≈ $59.94 Billion |
+15.13% |
| 2016-12-31 | €44.53 Billion ≈ $52.06 Billion |
+8.94% |
| 2015-12-31 | €40.88 Billion ≈ $47.79 Billion |
+12.65% |
| 2014-12-31 | €36.29 Billion ≈ $42.43 Billion |
+26.84% |
| 2013-12-31 | €28.61 Billion ≈ $33.45 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sinopharm Group Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 850.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €53.74 Billion | 68.13% |
| Other Components | €25.14 Billion | 31.87% |
| Total Equity | €78.88 Billion | 100.00% |
Sinopharm Group Co. Ltd Competitors by Market Cap
The table below lists competitors of Sinopharm Group Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NBTM New Materials Group Co Ltd
SHG:600114
|
$3.15 Billion |
|
Turkiye Sigorta AS
IS:TURSG
|
$3.15 Billion |
|
Jumbo S.A.
AT:BELA
|
$3.15 Billion |
|
United States Lime & Minerals Inc
NASDAQ:USLM
|
$3.15 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
$3.15 Billion |
|
Wienerberger AG
VI:WIE
|
$3.15 Billion |
|
Shanghai Lingang Holdings Co Ltd A
SHG:600848
|
$3.15 Billion |
|
Iskenderun Demir ve Celik AS
IS:ISDMR
|
$3.15 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinopharm Group Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 74,582,217,000 to 78,883,795,000, a change of 4,301,578,000 (5.8%).
- Net income of 7,049,683,000 contributed positively to equity growth.
- Dividend payments of 2,714,862,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €7.05 Billion | +8.94% |
| Dividends Paid | €2.71 Billion | -3.44% |
| Other Changes | €-33.24 Million | -0.04% |
| Total Change | €- | 5.77% |
Book Value vs Market Value Analysis
This analysis compares Sinopharm Group Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €12.74 | €2.01 | x |
| 2018-12-31 | €14.41 | €2.01 | x |
| 2019-12-31 | €15.96 | €2.01 | x |
| 2020-12-31 | €18.06 | €2.01 | x |
| 2021-12-31 | €19.83 | €2.01 | x |
| 2022-12-31 | €21.81 | €2.01 | x |
| 2023-12-31 | €23.90 | €2.01 | x |
| 2024-12-31 | €25.28 | €2.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinopharm Group Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.94%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.21%
- • Asset Turnover: 1.49x
- • Equity Multiplier: 4.98x
- Recent ROE (8.94%) is below the historical average (12.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 10.31% | 1.35% | 1.58x | 4.83x | €68.45 Million |
| 2014 | 10.50% | 1.44% | 1.56x | 4.70x | €136.64 Million |
| 2015 | 12.53% | 1.65% | 1.64x | 4.63x | €761.19 Million |
| 2016 | 14.61% | 1.80% | 1.64x | 4.96x | €1.47 Billion |
| 2017 | 14.98% | 1.91% | 1.63x | 4.81x | €1.76 Billion |
| 2018 | 13.63% | 1.69% | 1.46x | 5.51x | €1.55 Billion |
| 2019 | 13.18% | 1.47% | 1.57x | 5.69x | €1.51 Billion |
| 2020 | 12.75% | 1.57% | 1.47x | 5.52x | €1.55 Billion |
| 2021 | 12.54% | 1.49% | 1.55x | 5.42x | €1.57 Billion |
| 2022 | 12.53% | 1.54% | 1.51x | 5.36x | €1.72 Billion |
| 2023 | 12.14% | 1.52% | 1.56x | 5.14x | €1.60 Billion |
| 2024 | 8.94% | 1.21% | 1.49x | 4.98x | €-838.70 Million |
Industry Comparison
This section compares Sinopharm Group Co. Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $2,553,465,161
- Average return on equity (ROE) among peers: -12.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinopharm Group Co. Ltd (X2S) | €129.26 Billion | 10.31% | 2.25x | $3.15 Billion |
| AKSO HEALTH GR. (SPADR)/3 (8HX) | $12.29 Million | -137.16% | 4.11x | $1.60 Billion |
| EDAP TMS S.A (EDA) | $26.25 Million | -7.45% | 1.10x | $105.70 Million |
| Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) | $19.26 Billion | 10.70% | 0.47x | $457.61 Million |
| Medios AG (ILM1) | $510.19 Million | 2.46% | 0.83x | $311.23 Million |
| M1 Kliniken AG (M12) | $29.75 Million | 22.29% | 0.12x | $300.08 Million |
| Paragon Care Limited (PXS) | $121.52 Million | 6.81% | 1.40x | $152.88 Million |
| Sigma Healthcare Limited (S5YA) | $477.77 Million | 0.38% | 1.46x | $18.92 Billion |
| TELES Informationstechnologien AG (TLIK) | $-13.19 Million | 0.00% | 0.00x | $2.22 Million |
About Sinopharm Group Co. Ltd
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more